GlassScriptPhysician profile
Carissa R Mitchell
NPI 1053081703
$1,281.66
in general payments reported to CMS, 2019-2025
19 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $362 · 2024: $134 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.90 |
| Education | $348.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $194.74 | 2025 | Trodelvy |
| Seagen INC. | $182.22 | 2023 | Tukysa |
| Daiichi Sankyo INC. | $176.66 | 2025 | Enhertu |
| Incyte Corporation | $120.81 | 2022-2023 | Monjuvi |
| Janssen Biotech, INC. | $118.34 | 2022-2025 | Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $97.93 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $64.99 | 2023 | |
| Sobi, INC | $63.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $54.80 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $34.03 | 2024-2025 | Lynozyfic, Libtayo |
| Jazz Pharmaceuticals INC. | $30.00 | 2023 | |
| Genentech USA, INC. | $23.08 | 2024 | Venclexta |
| Array Biopharma INC | $22.55 | 2025 | Mektovi, Braftovi, Lorbrena |
| Stemline Therapeutics INC. | $19.99 | 2025 | Orserdu |
| Pfizer INC. | $18.88 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $15.91 | 2024 | |
| Eisai INC. | $14.79 | 2023 | |
| Taiho Oncology, INC. | $14.77 | 2023 | |
| Astellas Pharma US INC | $13.56 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carissa Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.